Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.61 |
| ▸ | PPARA | Q07869 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 10/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | MPC2 | O95563 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930674 | 1.00 | FFAR1 (0.61) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL6381220 | 0.87 | FFAR1 (0.65) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL19217676 | 0.86 | FFAR1 (0.61) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL12515224 | 0.86 | FFAR1 (0.69) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL6931105 | 0.85 | PPARG (0.70) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL6379645 | 0.84 | PPARG (0.55) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL9564659 | 0.84 | FFAR1 (0.62) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL12515223 | 0.84 | FFAR1 (0.66) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL21504774 | 0.82 | FFAR1 (0.59) | FFAR1PPARAPPARGCYP3A4RXRA | |
| SCHEMBL8003801 | 0.82 | FFAR1 (0.56) | FFAR1PPARAPPARGCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |